MagForce AG publishes Shareholder Letter

MagForce AG publishes Shareholder Letter

BERLIN, Nov. 8, 2013 (GLOBE NEWSWIRE) --

Dear MagForce Shareholders,

I am pleased to report that we are on target to achieve our 2013 plans:

Brain Cancer Therapy: Our main objective for 2013 is to initiate our post-
marketing clinical study in recurrent Glioblastoma patients with the placement
of NanoActivators® in three world class hospitals in Germany. During September
and October we installed our second NanoActivator® at Münster University
Hospital. We expect to install the third NanoActivator® by year end and the
fourth will be installed in early 2014. Initiation of the new Glioblastoma
clinical study is on schedule to start in 2013. In addition, we are preparing
our registration path for the USA. In the near future, we intend to concentrate
on recurrent Glioblastoma Multiforme (GBM) in Germany, EU27 and the USA, which
represents approximately 30% of the approximately 133,000 new GBM cases
diagnosed annually. Parallel to the study we also expect to treat patients
commercially already in 2014, as not every patient with GBM qualifies for the
study, but can of course already profit from our approach. Global healthcare
expenses for GBM treatments are estimated to exceed 2 billion Euros per year.

Prostate Cancer Therapy: With respect to the application of MagForce's
NanoTherm® Therapy (NTT) to the treatment of prostate cancer, our unique
technology is viewed as a very promising compliment to current prostate cancer
treatments. Our short-term task is to define the optimum regimen with our
NanoTherm® Therapy technology and the path to commercialization. As I discussed
in my letter to you in July, we plan to have the path defined and start the
execution process by the end of Q4, 2013. We are on target to accomplish this
2013 goal also. Of the 900,000 new diagnosed prostate cancer cases each year,
approximately 57% are diagnosed in the combined regions of the USA, Germany and
EU27 countries. The combined healthcare expenditure to treat prostate cancer in
these regions is estimated to exceed 10 billion Euros.

Financial: Our spending is on target; however, as I indicated in my letter to
you with the half-year results, we expect the net loss from operating activities
to be higher than in 2012, largely due to the start of the new clinical
Glioblastoma study and to preparations for market entry in other countries.

Investor Relations: As we are defining our corporate goals and path to achieve
them, I would like to point out that we will continue to present at conferences
as in the past. Our first presentation is Tuesday, November 12(th) in Frankfurt
at EIGENKAPITALFORUM. Investors who are attending the event are cordially
invited to join my presentation. I am very much looking forward to the personal
discussion with you.

Personnel: I am very pleased to reiterate that we have a management team and
employees who are very dedicated and very talented. I am particularly pleased
that the Supervisory Board of MagForce AG has approved the distribution of
MagForce stock options to every employee! In detail, we have 1,790,499 options
outstanding under the 2013 plan. The term is 6 years with an earliest exercise
after 4 years which assumes we are fully aligned with our shareholders and focus
on sustainable shareholder value.

Dear Shareholders, in summary we have a challenging path to develop and expand
our NanoTherm®Therapy into a valued therapy for the treatment of GBM and
prostate cancer and achieve our 5 year financial target which calls for annual
revenues between 100-150 Million Euros. We are enthusiastically making progress
step by step. Again, thank you for your interest and support of MagForce AG.


Dr. Ben Lipps

Chief Executive Officer &

Chairman of the Management Board

About MagForce AG
MagForce AG is a leading medical device company in the field of nanomedicine in
oncology, listed in the entry standard (MF6). The Company's proprietary,
NanoTherm® therapy, enables the targeted treatment of solid tumors through the
intratumoral generation of heat via activation of superparamagnetic
nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator® are components of the
therapy and have received EU-wide regulatory approval as medical devices for the
treatment of brain tumors. MagForce, NanoTherm®, NanoPlan®, and NanoActivator®
are trademarks of MagForce AG in selected countries. For more information,
please visit

This release may contain forward-looking statements and information which may be
identified by formulations using terms such as "expects", "aims", "anticipates",
"intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-
looking statements are based on our current expectations and certain
assumptions, which may be subject to a variety of risks and uncertainties. The
results actually achieved by MagForce AG may substantially differ from these
forward-looking statements. MagForce AG assumes no obligation to update these
forward-looking statements or to correct them in case of developments, which
differ from those, anticipated.

MagForce_Shareholder Letter_Nov 08, 2013:


CONTACT: For further information:
         Anne Hennecke
         MC Services AG
         T +49 211 529252 22
         F +49 211 529252 29
         M +49 151 12 555 759
Press spacebar to pause and continue. Press esc to stop.